AVEO Pharmaceuticals (NASDAQ: AVEO) announced that additional biomarker analyses from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE